{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T11:10:34Z","timestamp":1785928234149,"version":"3.56.0"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Brain, Behavior, and Immunity"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.bbi.2019.09.006","type":"journal-article","created":{"date-parts":[[2019,9,7]],"date-time":"2019-09-07T10:55:52Z","timestamp":1567853752000},"page":"372-381","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"special_numbering":"C","title":["Endocannabinoid modulation of inflammatory hyperalgesia in the IFN-\u03b1 mouse model of depression"],"prefix":"10.1016","volume":"82","author":[{"given":"Marie","family":"Fitzgibbon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel M.","family":"Kerr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca J.","family":"Henry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David P.","family":"Finn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Roche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbi.2019.09.006_b0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neubiorev.2019.07.007","article-title":"Evaluation of the Wistar-Kyoto rat model of depression and the role of synaptic plasticity in depression and antidepressant response","volume":"105","author":"Aleksandrova","year":"2019","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.bbi.2019.09.006_b0010","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/0006-291X(81)91284-5","article-title":"Human leukocyte interferon (HuIFN-alpha): potent endorphin-like opioid activity","volume":"101","author":"Blalock","year":"1981","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bbi.2019.09.006_b0015","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1111\/j.1476-5381.2011.01445.x","article-title":"The fatty acid amide hydrolase (FAAH) inhibitor PF-3845 acts in the nervous system to reverse LPS-induced tactile allodynia in mice","volume":"165","author":"Booker","year":"2012","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bbi.2019.09.006_b0020","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1007\/s00213-015-4105-9","article-title":"Crosstalk between endocannabinoid and immune systems: a potential dysregulation in depression?","volume":"233","author":"Boorman","year":"2016","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.bbi.2019.09.006_b0025","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/j.neuroscience.2010.10.030","article-title":"Enhanced nociceptive responding in two rat models of depression is associated with alterations in monoamine levels in discrete brain regions","volume":"171","author":"Burke","year":"2010","journal-title":"Neuroscience"},{"key":"10.1016\/j.bbi.2019.09.006_b0030","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1159\/000435931","article-title":"Neuroinflammatory mechanisms linking pain and depression","volume":"30","author":"Burke","year":"2015","journal-title":"Mod. Trends Pharmacopsychiatry"},{"key":"10.1016\/j.bbi.2019.09.006_b0035","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1002\/jnr.23802","article-title":"Psychological stress in early life as a predisposing factor for the development of chronic pain: clinical and preclinical evidence and neurobiological mechanisms","volume":"95","author":"Burke","year":"2017","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.bbi.2019.09.006_b0040","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/S0893-133X(01)00407-9","article-title":"Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions","volume":"26","author":"Capuron","year":"2002","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.bbi.2019.09.006_b0045","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/bs.irn.2015.10.003","article-title":"The role of the brain's endocannabinoid system in pain and its modulation by stress","volume":"125","author":"Corcoran","year":"2015","journal-title":"Int. Rev. Neurobiol."},{"key":"10.1016\/j.bbi.2019.09.006_b0050","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1155\/2008\/725702","article-title":"Evaluation of oral cannabinoid-containing medications for the management of interferon and ribavirin-induced anorexia, nausea and weight loss in patients treated for chronic hepatitis C virus","volume":"22","author":"Costiniuk","year":"2008","journal-title":"Can. J. Gastroenterol."},{"key":"10.1016\/j.bbi.2019.09.006_b0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bbi.2014.06.007","article-title":"The endocannabinoid system modulates stress, emotionality, and inflammation","volume":"42","author":"Crowe","year":"2014","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.bbi.2019.09.006_b0060","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.bbr.2007.05.005","article-title":"The widely-used anti-viral drug interferon-alpha induces depressive- and anxiogenic-like effects in healthy rats","volume":"182","author":"Fahey","year":"2007","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.bbi.2019.09.006_b0065","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.physbeh.2015.12.013","article-title":"Interferon-alpha-induced inflammation is associated with reduced glucocorticoid negative feedback sensitivity and depression in patients with hepatitis C virus","volume":"166","author":"Felger","year":"2016","journal-title":"Physiol. Behav."},{"key":"10.1016\/j.bbi.2019.09.006_b0070","doi-asserted-by":"crossref","first-page":"pyv095","DOI":"10.1093\/ijnp\/pyv095","article-title":"High times for painful blues: the endocannabinoid system in pain-depression comorbidity","volume":"19","author":"Fitzgibbon","year":"2015","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.bbi.2019.09.006_b0075","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.bbr.2018.06.030","article-title":"FAAH inhibition attenuates TLR3-mediated hyperthermia, nociceptive- and anxiety-like behaviour in female rats","volume":"353","author":"Flannery","year":"2018","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.bbi.2019.09.006_b0080","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.bbi.2012.11.010","article-title":"Poly I:C-induced activation of the immune response is accompanied by depression and anxiety-like behaviours, kynurenine pathway activation and reduced BDNF expression","volume":"28","author":"Gibney","year":"2013","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.bbi.2019.09.006_b0085","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1111\/j.1476-5381.2010.01192.x","article-title":"Peripheral antinociceptive effects of inhibitors of monoacylglycerol lipase in a rat model of inflammatory pain","volume":"163","author":"Guindon","year":"2011","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bbi.2019.09.006_b0090","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.bbi.2012.07.023","article-title":"Central administration of murine interferon-alpha induces depressive-like behavioral, brain cytokine and neurochemical alterations in mice: a mini-review and original experiments","volume":"31","author":"Hayley","year":"2013","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.bbi.2019.09.006_b0095","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.jneuroim.2014.09.002","article-title":"FAAH-mediated modulation of TLR3-induced neuroinflammation in the rat hippocampus","volume":"276","author":"Henry","year":"2014","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.bbi.2019.09.006_b0100","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.pnpbp.2015.03.006","article-title":"For whom the endocannabinoid tolls: Modulation of innate immune function and implications for psychiatric disorders","volume":"64","author":"Henry","year":"2016","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.bbi.2019.09.006_b0105","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.bbi.2017.02.016","article-title":"Pharmacological inhibition of FAAH modulates TLR-induced neuroinflammation, but not sickness behaviour: an effect partially mediated by central TRPV1","volume":"62","author":"Henry","year":"2017","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.bbi.2019.09.006_b0110","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.bbi.2014.06.200","article-title":"Insights from interferon-alpha-related depression for the pathogenesis of depression associated with inflammation","volume":"42","author":"Hoyo-Becerra","year":"2014","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.bbi.2019.09.006_b0115","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.neuroscience.2012.09.067","article-title":"Brain CB(1) receptor expression following lipopolysaccharide-induced inflammation","volume":"227","author":"Hu","year":"2012","journal-title":"Neuroscience"},{"key":"10.1016\/j.bbi.2019.09.006_b0120","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.3892\/mmr.2016.5585","article-title":"Endocannabinoid system: role in depression, reward and pain control (Review)","volume":"14","author":"Huang","year":"2016","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.bbi.2019.09.006_b0125","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/0304-3959(87)90088-1","article-title":"The formalin test in mice: dissociation between inflammatory and non-inflammatory pain","volume":"30","author":"Hunskaar","year":"1987","journal-title":"Pain"},{"key":"10.1016\/j.bbi.2019.09.006_b0130","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/0304-3959(86)90014-X","article-title":"Dissociation between antinociceptive and anti-inflammatory effects of acetylsalicylic acid and indomethacin in the formalin test","volume":"25","author":"Hunskaar","year":"1986","journal-title":"Pain"},{"key":"10.1016\/j.bbi.2019.09.006_b0135","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pneurobio.2014.06.003","article-title":"Stress-induced hyperalgesia","volume":"121","author":"Jennings","year":"2014","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.bbi.2019.09.006_b0140","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S0197-0186(99)00124-2","article-title":"Analgesic effect of interferon-alpha via mu opioid receptor in the rat","volume":"36","author":"Jiang","year":"2000","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.bbi.2019.09.006_b0145","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.bbi.2016.04.001","article-title":"Why sickness hurts: a central mechanism for pain induced by peripheral inflammation","volume":"57","author":"Karshikoff","year":"2016","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.bbi.2019.09.006_b0150","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.neuroscience.2011.09.032","article-title":"Pharmacological inhibition of endocannabinoid degradation modulates the expression of inflammatory mediators in the hypothalamus following an immunological stressor","volume":"204","author":"Kerr","year":"2012","journal-title":"Neuroscience"},{"key":"10.1016\/j.bbi.2019.09.006_b0155","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1111\/j.1476-5381.2012.02237.x","article-title":"The monoacylglycerol lipase inhibitor JZL184 attenuates LPS-induced increases in cytokine expression in the rat frontal cortex and plasma: differential mechanisms of action","volume":"169","author":"Kerr","year":"2013","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bbi.2019.09.006_b0160","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1007\/s12272-010-0712-5","article-title":"Interaction of supraspinally administered interferon-alpha with opioid system in the production of antinociception","volume":"33","author":"Lee","year":"2010","journal-title":"Arch. Pharm. Res."},{"key":"10.1016\/j.bbi.2019.09.006_b0165","doi-asserted-by":"crossref","first-page":"34356","DOI":"10.1038\/srep34356","article-title":"Interferon alpha inhibits spinal cord synaptic and nociceptive transmission via neuronal-glial interactions","volume":"6","author":"Liu","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbi.2019.09.006_b0170","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/npp.2014.198","article-title":"Therapeutic potential of inhibitors of endocannabinoid degradation for the treatment of stress-related hyperalgesia in an animal model of chronic pain","volume":"40","author":"Lomazzo","year":"2015","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.bbi.2019.09.006_b0175","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1006\/abbi.2001.2500","article-title":"Lipopolysaccharide downregulates fatty acid amide hydrolase expression and increases anandamide levels in human peripheral lymphocytes","volume":"393","author":"Maccarrone","year":"2001","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.bbi.2019.09.006_b0180","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1177\/0897190011415687","article-title":"Side effects of the therapy with peginterferon and ribavirin in chronic hepatitis C: a small audit","volume":"25","author":"Nogueira","year":"2012","journal-title":"J. Pharm. Pract."},{"key":"10.1016\/j.bbi.2019.09.006_b0185","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/sj.mp.4002148","article-title":"Lipopolysaccharide-induced depressive-like behavior is mediated by indoleamine 2,3-dioxygenase activation in mice","volume":"14","author":"O'Connor","year":"2009","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.bbi.2019.09.006_b0190","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.neulet.2012.02.087","article-title":"5-HT(1A) receptor and apoptosis contribute to interferon-alpha-induced \u201cdepressive-like\u201d behavior in mice","volume":"514","author":"Ping","year":"2012","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.bbi.2019.09.006_b0195","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1016\/j.neuroscience.2009.01.072","article-title":"Neurochemical and behavioral alterations in an inflammatory model of depression: sex differences exposed","volume":"159","author":"Pitychoutis","year":"2009","journal-title":"Neuroscience"},{"key":"10.1016\/j.bbi.2019.09.006_b0200","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2165\/00023210-200519020-00002","article-title":"Neuropsychiatric adverse effects of interferon-alpha: recognition and management","volume":"19","author":"Raison","year":"2005","journal-title":"CNS Drugs"},{"key":"10.1016\/j.bbi.2019.09.006_b0205","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.pain.2013.09.012","article-title":"Impaired endocannabinoid signalling in the rostral ventromedial medulla underpins genotype-dependent hyper-responsivity to noxious stimuli","volume":"155","author":"Rea","year":"2014","journal-title":"Pain"},{"key":"10.1016\/j.bbi.2019.09.006_b0210","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.yhbeh.2012.03.010","article-title":"Indoleamine 2,3-dioxygenase mediates anhedonia and anxiety-like behaviors caused by peripheral lipopolysaccharide immune challenge","volume":"62","author":"Salazar","year":"2012","journal-title":"Horm. Behav."},{"key":"10.1016\/j.bbi.2019.09.006_b0215","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1016\/j.neuropharm.2012.08.009","article-title":"Peripheral antinociceptive effect of anandamide and drugs that affect the endocannabinoid system on the formalin test in normal and streptozotocin-diabetic rats","volume":"63","author":"Schreiber","year":"2012","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bbi.2019.09.006_b0220","first-page":"6","article-title":"Frequency of depression and somatic symptoms in patients on interferon alpha\/ribavirin for chronic hepatitis C","volume":"22","author":"Shakoor","year":"2010","journal-title":"J. Ayub. Med. Coll. Abbottabad"},{"key":"10.1016\/j.bbi.2019.09.006_b0225","doi-asserted-by":"crossref","first-page":"239","DOI":"10.4103\/0019-5545.86815","article-title":"Development of a murine animal model of depression for repeated dosing with human interferon alpha","volume":"53","author":"Siddegowda","year":"2011","journal-title":"Indian J. Psychiatry"},{"key":"10.1016\/j.bbi.2019.09.006_b0230","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/bs.apha.2017.05.003","article-title":"Cannabinoids and pain: sites and mechanisms of action","volume":"80","author":"Starowicz","year":"2017","journal-title":"Adv. Pharmacol."},{"key":"10.1016\/j.bbi.2019.09.006_b0235","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbi.2019.04.032","article-title":"Interferon-alpha-induced depression: comparisons between early- and late-onset subgroups and with patients with major depressive disorder","author":"Su","year":"2019","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.bbi.2019.09.006_b0240","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.4088\/JCP.12r07694","article-title":"Interferon-induced depression in chronic hepatitis C: a systematic review and meta-analysis","volume":"73","author":"Udina","year":"2012","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.bbi.2019.09.006_b0245","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1124\/pr.113.008144","article-title":"Neuroinflammation and comorbidity of pain and depression","volume":"66","author":"Walker","year":"2014","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.bbi.2019.09.006_b0250","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.neulet.2005.12.046","article-title":"mu- but not delta- and kappa-opioid receptor mediates the nucleus submedius interferon-alpha-evoked antinociception in the rat","volume":"397","author":"Wang","year":"2006","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.bbi.2019.09.006_b0255","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1124\/jpet.115.229971","article-title":"The selective monoacylglycerol lipase inhibitor MJN110 produces opioid-sparing effects in a mouse neuropathic pain model","volume":"357","author":"Wilkerson","year":"2016","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bbi.2019.09.006_b0260","series-title":"Proceedings of the International College of Neuropsychpharmacology Thematic Meeting","first-page":"P072","article-title":"The Endocannabinoid System in Interferon-alpha (IFN-\u03b1) induced depression and stress response","author":"Zajkowska","year":"2015"}],"container-title":["Brain, Behavior, and Immunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889159119306063?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889159119306063?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:56:17Z","timestamp":1760169377000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889159119306063"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":52,"alternative-id":["S0889159119306063"],"URL":"https:\/\/doi.org\/10.1016\/j.bbi.2019.09.006","relation":{},"ISSN":["0889-1591"],"issn-type":[{"value":"0889-1591","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Endocannabinoid modulation of inflammatory hyperalgesia in the IFN-\u03b1 mouse model of depression","name":"articletitle","label":"Article Title"},{"value":"Brain, Behavior, and Immunity","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbi.2019.09.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}